Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03175172 · ClinicalTrials.gov registry record · Phase 2
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
A Phase 2 study, sponsored by Aduro Biotech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03175172: Clinical Trial Phase 2 study, sponsored by Aduro Biotech.
NCT03175172 is a Phase 2 study that was terminated before completion, run by Aduro Biotech. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03175172, a Phase 2 study, was terminated before completion, sponsored by Aduro Biotech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL CRS-207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03175172
The ClinicalTrials.gov registry entry for NCT03175172 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aduro Biotech, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03175172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03175172 about?
NCT03175172 is a clinical study titled "Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)". The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.
What is the current status of trial NCT03175172?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-05-31. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT03175172?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CRS-207 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03175172?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.